Risk of new-onset heart failure and heart failure exacerbations following COVID-19, influenza or respiratory-syncytial-virus hospitalisation
- PMID: 41206580
- DOI: 10.1093/eurjpc/zwaf714
Risk of new-onset heart failure and heart failure exacerbations following COVID-19, influenza or respiratory-syncytial-virus hospitalisation
Abstract
Background: While acute respiratory-viral-infection (RVI) is associated with elevated short-term risk of concurrent cardiac events, less is known regarding subsequent heart-failure (HF) risk post-RVI hospitalisation. We evaluated risk of HF post-hospitalisation for influenza/COVID-19/respiratory-syncytial-virus(RSV).
Methods: Population-based retrospective cohort study, including all adult Singaporeans (≥18 years) hospitalised for influenza/COVID-19/RSV (01/01/2017-30/08/2023); stratified by pre-existing HF. Risks of acute HF (new-onset/readmission) post-RVI-hospitalisation was compared against controls (orthopaedic hospitalisations) using overlap-weighted competing-risks-regression. HF was ascertained using national healthcare-claims data. Analyses were further stratified by RVI type and vaccination status.
Results: Amongst individuals without pre-existing HF (N=59,408) hospitalised for RVI (influenza/COVID-19/RSV), overall risk of new-onset HF up to 180 days post-hospitalisation was elevated versus controls (adjusted-hazards-ratio, aHR=1.45[95%CI=1.26-1.67]). Risk of new-onset HF was observed up to 180 days post-hospitalisation for specific RVIs (RSV: aHR=2.03[95%CI=1.26-3.25]; COVID-19: aHR=1.36[95%CI=1.16-1.60]; influenza: aHR=1.62[95%CI=1.28-2.06]); however, risk was not significantly increased amongst influenza hospitalisations vaccinated <365 days prior (aHR=1.47[95%CI=0.82-2.64]). In HF patients (N=4163) hospitalised for RVI(influenza/COVID-19/RSV), risk of HF readmission was similarly increased (aHR=1.28[95%CI=1.08-1.52]). No increased risk of HF readmission post-COVID-19 was observed amongst individuals who received ≥4 COVID-19 vaccine doses (aHR=0.86[95%CI=0.59-1.27]), or who were vaccinated <180 days prior (aHR=0.97[95%CI=0.79-1.20]). Similarly, risk of HF readmission post-influenza was not significantly increased amongst individuals vaccinated <365 days prior (aHR=1.63[95%CI=0.94-2.82]). Elevated risk of HF readmission post-RVI hospitalisation predominantly accrued in older patients (≥70 years).
Conclusions: RVIs can contribute to post-acute risk of new-onset HF and HF readmissions. Vaccination represents an opportunity for HF prevention amongst at-risk individuals.
Keywords: COVID-19; RSV; Respiratory viruses; heart failure; influenza.
Plain language summary
In a retrospective population-based cohort study, overall risk of new-onset heart-failure (HF) up to 180 days following hospitalisation for respiratory-viral-infection (RVI), including COVID-19/influenza/respiratory-syncytial-virus (RSV) was 45% higher than that of controls hospitalised for limb-injuries; similarly, 28% higher risk of HF readmission was observed up to 180 days following RVI hospitalisation (COVID-19/influenza/RSV) in a cohort with pre-existing HF, versus controls. Risk of new-onset HF and HF readmission was not significantly increased amongst influenza hospitalisations vaccinated <365 days prior; no increased risk of HF readmission post-COVID-19 was observed amongst individuals who received ≥4 COVID-19 vaccine doses/were vaccinated <180 days prior.Vaccination represents an opportunity for heart failure prevention, especially in at-risk individuals and older adults.
© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.